Skip to content

    Ulcerative Colitis Health Center

    Font Size
    A
    A
    A

    Simponi Approved for Ulcerative Colitis

    Blocks process that contributes to abnormal inflammation

    WebMD News from HealthDay

    By Scott Roberts

    HealthDay Reporter

    WEDNESDAY, May 15 (HealthDay News) -- Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

    The drug is designed to block tumor necrosis factor, which has a key role in causing abnormal inflammation and immune system responses, the FDA said Wednesday in a news release.

    The drug has already been approved to treat psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis, the agency said.

    Ulcerative colitis, affecting some 620,000 Americans, causes chronic inflammation and ulcers in the inner lining of the large intestine. Common symptoms include abdominal discomfort, gastrointestinal bleeding and diarrhea.

    Simponi was clinically evaluated in two studies involving more than 800 people. The most common side effects reported were upper respiratory infection and redness at the injection site. People treated with the drug are at greater-than-average risk of contracting several types of infection, lymphoma, heart failure, nervous system disorders and allergic reactions, the FDA said.

    The drug is marketed by Janssen Biotech Inc., based in Horsham, Pa.

    Today on WebMD

    basket of vegetables
    Article
    IBD Overview Slideshow
    Slideshow
     
    Ulcerative Colitis Managing Flares
    Slideshow
    what is ibs
    Article
     

    Supplements UC
    Video
    Ulcerative Colitis Health Check
    Tool
     
    Ulcerative Colitis Diet
    Slideshow
    Ulcerative Colitis Diet Yogurt
    Article
     

    Ulcerative Colitis Surgery
    Slideshow
    Ulcerative Colitis Medications
    Article
     
    Exercising When You Have A GI Disorder
    Article
    Picture Of The Intestines
    Image Collection